Three phase III trials for brolucizumab terminated early owing to high rates of ocular inflammation

Manufacturers are halting the MERLIN, RAPTOR and RAVEN studies, investigating the four week dosing interval, because of safety concerns due to more frequent incidences of retinal vasculitis and retinal vascular occlusion compared with the aflibercept 2 mg.

Source:

Biospace Inc.